Compare · INZY vs NVO
INZY vs NVO
Side-by-side comparison of Inozyme Pharma Inc. (INZY) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INZY and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 1182.8x INZY ($158.6M).
- Over the past year, INZY is up 0.5% and NVO is down 41.7% - INZY leads by 42.2 points.
- NVO has hit the wire 11 times in the past 4 weeks while INZY has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 8 for INZY).
- Company
- Inozyme Pharma Inc.
- Novo Nordisk A/S
- Price
- $4.00+0.13%
- $42.01-2.10%
- Market cap
- $158.6M
- $187.53B
- 1M return
- +0.50%
- -5.38%
- 1Y return
- +0.50%
- -41.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 11
- Recent ratings
- 8
- 25
Inozyme Pharma Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest INZY
- Amendment: SEC Form SCHEDULE 13G/A filed by Inozyme Pharma Inc.
- SEC Form 15-12G filed by Inozyme Pharma Inc.
- SVP, CFO & Head of BD Subramanian Sanjay closing all direct ownership in the company (SEC Form 4)
- COO Winton Matthew closing all direct ownership in the company (SEC Form 4)
- Director Bolte Axel closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Sullivan Lynne Marie
- CEO & Chairman Treco Douglas A closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Hopfner Robert Lorne
- SEC Form EFFECT filed by Inozyme Pharma Inc.
- SEC Form EFFECT filed by Inozyme Pharma Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates